Free Submission Public Relations &
Deutsch English


Cytokinetics to Present at Upcoming Healthcare Conferences

Print article Print article
Copyright © Thomson Reuters 2013. All rights reserved.
2013-02-22 22:02:39 -

South San Francisco, CA, February 22, 2013 - Cytokinetics, Incorporated (Nasdaq:
CYTK) announced today that members of its management team are scheduled to
participate at the following healthcare conferences:

Canaccord Genuity Orphan Drug One-on-One Day
Date: Monday, February 25(th)
Location: Omni Berkshire Place, New York, NY
Not webcast:  one-on-one meetings only
Attendees:  Sharon Barbari, Executive Vice President, Finance & Chief Financial
Officer; Fady Malik, MD, PhD, FACC, Senior Vice President, Research and Early

Cowen & Company 33(rd) Annual Health Care Conference
Date: Monday, March 4(th)
Time: 1:30 PM Eastern Time
Location: Boston Marriott Copley Place Hotel, Boston, Massachusetts
Presenter:  Robert I. Blum, President and Chief Executive Officer

Interested parties may access the live webcast of the Cowen & Company
presentation by visiting the Investor Relations section of the Cytokinetics
website at The webcast replay of 
the presentation will be archived on the Presentations page within the Investor Relations section of Cytokinetics' website for two weeks following the completion of the event. About Cytokinetics Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing tirasemtiv, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. Tirasemtiv is currently the subject of a Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials.  All of these drug candidates have arisen from Cytokinetics' muscle biology focused research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations, and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission. Contacts: Cytokinetics, Incorporated: Joanna (Jodi) L. Goldstein Manager, Corporate Communications and Marketing (650) 624-3000 This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Cytokinetics, Inc. via Thomson Reuters ONE [HUG#1680561]

Press Information:

Contact Person:

Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact | BidVertiser